|
Vicus Therapeutics
is a privately held, biopharmaceutical company focused
on developing oncology supportive care drug products for serious unmet medical needs.
These products
include: VT-122, in Phase 2 clinical trials for cancer cachexia; VT-211 and VT-212, in investigator-led
pilot trials for chemotherapy-induced oral mucositis and neutropenia; and VT-310, in pre-clinical evaluation
for cancer-related fatigue
|
